生物制剂治疗方案的安全管理:治疗前筛查与治疗后监测

2022-08-02 生物制剂小编 生物制剂Biotech

很多患者小伙伴在打生物制剂前后会疑惑:使用生物制剂治疗前筛查哪些项目,打了生物制剂复诊随访又需要哪些项目?

很多患者小伙伴在打生物制剂前后会疑惑:使用生物制剂治疗前筛查哪些项目,打了生物制剂复诊随访又需要哪些项目,今天根据一些生物制剂厂家医学部PPT整理一个表格分享给大家。

另外,还要注意生物制剂的禁忌症,一般是以下几个疾病:

  1. 感染:活动性、慢性或者局限性感染,以及个体有反复感染病史;

  2. 恶性肿瘤:非黑色素瘤皮肤癌,在治疗前以及治疗期间应该定期检查监测;

  3. 中重度心衰。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826052, encodeId=2ad31826052af, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 13 17:49:03 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085348, encodeId=6842208534810, content=<a href='/topic/show?id=956645e39dc' target=_blank style='color:#2F92EE;'>#安全管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45739, encryptionId=956645e39dc, topicName=安全管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun Apr 23 14:49:03 CST 2023, time=2023-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905212, encodeId=ee4419052129d, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 03 03:49:03 CST 2023, time=2023-06-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826052, encodeId=2ad31826052af, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 13 17:49:03 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085348, encodeId=6842208534810, content=<a href='/topic/show?id=956645e39dc' target=_blank style='color:#2F92EE;'>#安全管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45739, encryptionId=956645e39dc, topicName=安全管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun Apr 23 14:49:03 CST 2023, time=2023-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905212, encodeId=ee4419052129d, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 03 03:49:03 CST 2023, time=2023-06-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826052, encodeId=2ad31826052af, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Sep 13 17:49:03 CST 2022, time=2022-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085348, encodeId=6842208534810, content=<a href='/topic/show?id=956645e39dc' target=_blank style='color:#2F92EE;'>#安全管理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45739, encryptionId=956645e39dc, topicName=安全管理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=xinxin088, createdTime=Sun Apr 23 14:49:03 CST 2023, time=2023-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1905212, encodeId=ee4419052129d, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sat Jun 03 03:49:03 CST 2023, time=2023-06-03, status=1, ipAttribution=)]

相关资讯

EMI:台湾HIV感染者中性传播丙型肝炎病毒再感染:基因6型的新作用

研究表明,DAAs实现了非常高的持续病毒学应答率(SVR),随后与降低全因死亡率、肝脏相关并发症和肝细胞癌相关。

JIAS:多替拉韦钠片抗逆转录病毒疗法在HIV和肺结核合并感染中的实际应用和结果

在全球范围内,HIV治疗计划正在从非核苷类逆转录酶抑制剂(NNRTIs) ,如依法韦仑,过渡到多替拉韦钠片,因为它具有更好的疗效和耐受性,以及对HIV耐药性的高遗传屏障。

CID:在急性HIV感染期间开始以EFV和DTG为基础的抗逆转录病毒治疗后的免疫、认知和精神预后

2018年,世界卫生组织(世卫组织)将其首选的治疗初治PLWH的一线抗逆转录病毒疗法从EFV改为DTG。

LCAH:母亲抗逆转录病毒治疗对未感染HIV的儿童早期神经发育的影响

据估计,全世界有1540万未感染艾滋病毒(HEU)的儿童,占一些艾滋病毒负担高的国家每年新生儿的20%以上。

Pediatrics:性活跃青少年的年度性传播感染检测

鉴于青少年中STI的高发病率、感染的严重后果(包括盆腔炎和不孕症), 以及衣原体筛查的成本效益,美国妇产科学院建议对青少年和年轻成年人进行某种程度的性传播感染筛查。

JAMA Netw Open:美国新诊断为HIV感染者中脑膜炎球菌疫苗接种率

感染艾滋病毒的人患脑膜炎球菌病的风险增加4.5%到12.9倍。